子宫内膜异位症的临床试验:现状、反思、挑战和机遇  

作　　者：郭孙伟[1,2] 

机构地区：[1]复旦大学附属妇产科医院 [2]复旦大学上海医学院生物化学和分子生物学系,上海200011

出　　处：《现代妇产科进展》2014年第7期505-511,共7页Progress in Obstetrics and Gynecology

摘　　要：近半个世纪来,关于子宫内膜异位症(内异症)的论文数呈指数增长,反映出众多科研人员对这一个"谜一样"的疾病指数增长的兴趣。作为一个研究疾病的科学领域,内异症研究的终极目的是开发出更好的诊疗方法和药物。因此,内异症研究成功的重要标志是开发出新的、疗效更好的药物。而连接基础研究和临床实践的一个重要桥梁是评价治疗药物/方法的临床试验。本文对临床试验透明化进程中一些里程碑式的事件作简要叙述,展示内异症临床试验在国内外的现状,并反思中国妇产科学界所面临的、在内异症临床试验方面的机遇和挑战。In the last 50 years, the number of publications on endometriosis has been growing exponen-tially, a sign that there is a burgeoning interest in this ’enigmatic’ disease. As the ultimate goal of disease-fo-cused research such as that of endometriosis is to provide better clinical care, the discovery and successful de-velopment of truly innovative drugs represent the culmination in research. Therefore, one hallmark of success of endometriosis research endeavor is the development of novel and differentiated medicines for patients. An impor-tant intermediate linking basic research and clinical practice is the use of clinical trials that evaluate the safety and efficacy of compounds deemed to be promising in preclinical research. In this paper, I shall provide an o-verview on some milestone events leading to the more transparency of clinical trials, review the current status of clinical trials on endometriosis at home and abroad, and reflect on some challenges and opportunities now facing gynecologic workers in China in clinical trials on endometriosis.

关 键 词：子宫内膜异位症 临床试验 

分 类 号：R711.71[医药卫生—妇产科学]